Fate Therapeutics, Inc. (FATE) vs Palisade Bio, Inc. (PALI)
A side-by-side comparison of Fate Therapeutics, Inc. and Palisade Bio, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
FATE
Fate Therapeutics, Inc.
$2.29HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
PALI
Palisade Bio, Inc.
$1.49HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — FATE vs PALI
growth of $100 · dividends reinvested · last 10yFATE -18.2% (-2.0%/yr)PALI -100.0% (-71.2%/yr)FATE compounded faster over this window
Log scale — wide-divergence pair
FATE PALI
FATE vs PALI: by the numbers
- •FATE is the larger company ($267M vs $259M market cap).
- •Both run net losses; FATE's is the smaller (-1941.09% vs -6388.20% net margin).
Metrics side by side
Valuation
| Metric | FATE | PALI |
|---|---|---|
| P/S ratio | 41.12 | 517.27 |
| P/B ratio | 1.74 | 2.12 |
Profitability
| Metric | FATE | PALI |
|---|---|---|
| Gross margin | -94.12% | 0.00% |
| Operating margin | -2222.45% | 0.00% |
| Net margin | -1941.09% | -6388.20% |
| ROE | -82.12% | -26.24% |
| ROIC | -58.72% | -28.96% |
Growth (annualized)
| Metric | FATE | PALI |
|---|---|---|
| Revenue CAGR (5Y) | -32.98% | N/A |
| Total return CAGR (5Y) | -46.86% | -76.02% |
Frequently asked
- How have FATE and PALI total returns compared?
- Over the past 10 years, FATE delivered -2.31% and PALI delivered -71.24% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.